<DOC>
	<DOCNO>NCT01960192</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety FVD regiment ( fotemustine , teniposide dexamethasone ) patient primary CNS lymphoma .</brief_summary>
	<brief_title>Treatment Primary CNS Lymphoma</brief_title>
	<detailed_description>Primary CNS lymphoma ( PCNSL ) rare B-cell variant non-Hodgkin lymphoma confine brain , leptomeninges , spinal cord , eye . The optimum treatment patient PCNSL remain challenging present universally accept therapeutic approach patient newly diagnose disease . The purpose study evaluate efficacy safety FVD regiment ( fotemustine , teniposide dexamethasone ) contrast HD-MTX-Ara-C program patient primary CNS lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Fotemustine</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Teniposide</mesh_term>
	<criteria>Age range 1460 year old ; ECOG performance status 02 ; Estimated survival time &gt; 3 month Histological confirm PCNSL None chemotherapy radiotherapy previously use None chemotherapy contraindication : hemoglobin ≥ 90 g/dl , neutrophil ≥ 1.5×109/L , platelet ≥ 100×109/L , ALT AST ≤ 2×ULN , serum bilirubin ≤ 1.5×ULN , serum creatine ≤ 1.5×upper limitation normal ( ULN ) , Serum Albumin ≥ 30g/L , serum plasminogen normal ( Inclusion Criteria 1,3,6 group ) At least one measurable lesion None serious disease , cardiopulmonary function normal Pregnancy test woman reproductive age must negative Patients could follow None relative treatment include traditional Chinese medicine , immunotherapy , biotherapy except antibone metastasis therapy symptomatic treatment . volunteer sign informed consent . Disagreement blood sample collection Patients allergic drug regimen metabolic disorder Pregnant lactate woman Serious medical illness likely interfere participation Serious infection Primitive secondary tumor central nervous system Chemotherapy radiotherapy contraindication The evidence peripheral nervous disorder dysphrenia patient participate clinical trial patient take antitumor drug patient estimate unsuitable investigato</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>primary CNS lymphoma ; chemotherapy ;</keyword>
	<keyword>RR ; PFS ; OS</keyword>
</DOC>